Selective killing of tumors deficient in methylthioadenosine phosphorylase: A novel strategy

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Lubin, Martin ^a   Lubin, Adam ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Amtek   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE; 5' DEOXYADENOSINE; 5' METHYLTHIOADENOSINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; 6 METHYLPURINE; ADENINE; ADENINE PHOSPHORIBOSYLTRANSFERASE; ADENOSINE DERIVATIVE; FLUDARABINE; FLUOROURACIL; PHOSPHORIBOSYL PYROPHOSPHATE; TIOGUANINE; UNCLASSIFIED DRUG; 5'-DEOXYADENOSINE; 5'-METHYLTHIOADENOSINE PHOSPHORYLASE; DEOXYADENOSINE DERIVATIVE; DRUG DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CLONING; CELL COUNT; CELL KILLING; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; COCULTURE; COLONY FORMING CELL; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME DEFICIENCY; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; TUMOR CELL LINE; CELL DEATH; CELL LINE; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY;

ADENINE; CELL DEATH; CELL LINE; COCULTURE TECHNIQUES; DEOXYADENOSINES; DRUG SCREENING ASSAYS, ANTITUMOR; FLUOROURACIL; HUMANS; NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; THIOGUANINE;

EID: 66749168748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005735     Document Type: Article

References (42)

1. Pegg AE, Williams-Ashman HG (1969) Phosphate-stimulated breakdown of 5′-methylthioadenosine by rat ventral prostate. Biochem J 115: 241-247.
2. Williams-Ashman HG, Seidenfeld J, Galletti P (1982) Trends in the biochemical pharmacology of 5′-deoxy-5′-methylthioadenosine. Biochem Pharmacol 31: 277-288.
3. Toohey JI (1978) Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells. Biochem Biophys Res Commun 83: 27-35.
4. Nobori T, Szinai I, Amox D, Parker B, Olopade OI, et al. (1993) Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers. Cancer Res 53: 1098-1101.
5. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32.
6. Karikari CA, Mullendore M, Eshleman JR, Argani P, Leoni LM, et al. (2005) Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. Mol Cancer Ther 4: 1860-1866.
7. Illei PB, Rusch VW, Zakowski MF, Ladanyi M (2003) Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 9: 2108-2113.
8. García-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, et al. (2002) Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 8: 782-787.
9. Li W, Su D, Mizobuchi H, Martin DS, Gu B, et al. (2004) Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells. Oncol Res 14: 373-379.
10. Nobori T, Karras JG, Della Ragione F, Waltz TA, Chen PP, et al. (1991) Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 51: 3193-3197.
11. Batova A, Diccianni MB, Nobori T, Vu T, Yu J, et al. (1996) Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood 88: 3083-3090.
12. Behrmann I, Wallner S, Komyod W, Heinrich PC, Schuierer M, et al. (2003) Characterization of methylthioadenosine phosphorylase (MTAP) expression in malignant melanoma. Am J Pathol 163: 683-690.
13. Della Ragione F, Russo G, Oliva A, Mastropietro S, Mancini A, et al. (1995) 5′-Deoxy-5′-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines. Oncogene 10: 827-833.
14. Kamatani N, Nelson-Rees WA, Carson DA (1981) Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci USA 78: 1219-1223.
15. Bloom LA, Boritzki TJ, Ogden R, et al. (3959) 2004 Mar 4.
16. ClinicalTrials. gov Identifier: NCT00062283. Alanosine in Treating Patients With Cancer.
17. ClinicalTrials.gov Identifier: NCT00075894. Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas.
18. Kindler HL, Burris HA 3rd, Sandler AB, Oliff IA (2008) A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs Epub Jul 1.
19. Tisdale MJ (1983) Methionine synthesis from 5′-methylthioadenosine by tumour cells. Biochem Pharmacol 32: 2915-2920.
20. Burchenal JH, Karnofsky DA, Kingsley-Pillers EM, Southam CM, Myers WP, et al. (1951) The effects of the folic acid antagonists and 2,6-diaminopurine on neoplastic disease, with special reference to acute leukemia. Cancer 4: 549-569.
21. Gadi VK, Alexander SD, Waud WR, Allan PW, Parker WB, et al. (2003) A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J Pharmacol Exp Ther 304: 1280-1284.
22. Zhang Y, Parker WB, Sorscher EJ, Ealick SE (2005) PNP anticancer gene therapy. Curr Top Med Chem 5: 1259-1274.
23. Santelli G, Valeriote F (1980) In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J Natl Cancer Inst 64: 69-72.
24. Heimer R, Goldberg D, Cadman E (1983) Modulation of fluoropyrimidine metabolism in L1210 cells by L-alanosine. Biochem Pharmacol 32: 199-206.
25. Hashimoto H, Kubota M, Shimizu T, Takimoto T, Kitoh T, et al. (1990) Biochemical basis of the prevention of 6-thiopurine toxicity by the nucleobases, hypoxanthine and adenine. Leuk Res 14: 1061-1066.
26. Riscoe MK, Ferro AJ (1984) 5-Methylthioribose. Its effects and function in mammalian cells. J Biol Chem 259: 5465-5471.
27. Russo GL, Della Ragione F, Utili R, Andreana A, Ruggiero G, et al. (1988) Studies on human serum 5′-deoxy-5′methylthioadenosine phosphorylase: molecular properties and clinical perspectives. In: Zappia V, Pegg A, eds. Advances in Experimental Medicine and Biology, vol. 250, Progress in Polyamine Research. New York: Plenum Press. pp 229-238.
28. Simile MM, Banni S, Angioni E, Carta G, De Miglio MR, et al. (2001) 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. J Hepatol 34: 386-394.
29. Wolford RW, Riscoe MK, Johnson L, Ferro AJ, Fitchen JH (1984) Effect of 5′-methylthioadenosine (a naturally occurring nucleoside) on murine hematopoiesis. Exp Hematol 12: 867-871.
30. Moratti EM inventor, Bioresearch SPA assignee (1998) Pharmaceutical compositions containing 5′-deoxy-5′-methylthioadenosine S-adenosylmethionine and their salts for reducing seborrhea. United States Patent 5,753,213.
31. Ikeguchi Y, Bewley M, Pegg AE (2006) Aminopropyltransferases: function, structure and genetics. J Biochem 139: 1-9.
32. Wu H, Min J, Zeng H, McCloskey DE, Ikeguchi Y, et al. (2008) Crystal structure of human spermine synthase: implications of substrate binding and catalytic mechanism. J Biol Chem 283: 16135-16146.
33. Pegg AE, Borchardt RT, Coward JK (1981) Effects of inhibitors of spermidine and spermine synthesis on polyamine concentrations and growth of transformed mouse fibroblasts. Biochem J 194: 79-89.
34. Lubin M, Lubin A (2009) Strategy for selective killing of tumors deficient in methylthioadenosine phosphorylase (MTAP): a progress report. Proceedings of the American Association for Cancer Research. Supplement: Late-Breaking Abstract LB-29.
35. Montgomery JA, Shortnacy AT, Thomas HJ (1974) Analogs of 5′-deoxy - 5′-(methylthio)adenosine. J. Med. Chem 17: 1197-1207.
36. Savarese TM, Chu SH, Chu MY, Parks RE (1984) 5′-Deoxy-5′-methylthioadenosine phosphorylase - III. Biochem. Pharmac 34: 361-367.
37. Kung PP, Zehnder LR, Meng JJ, Kupchinsky SW, Skalitzky DJ, et al. (2005) Design, synthesis, and biological evaluation of novel human 5′-deoxy-5′-methylthioadenosine phosphorylase (MTAP) substrates. Bioorg Med Chem Lett 15: 2829-2833.
38. Sufrin JR, Spiess AJ, Marasco CJ, Rattendi D, Bacchi CJ (2008) Novel trypanocidal analogs of 5′-(methylthio)-adenosine. Antimicrob. Agents Chemother 52: 211-219.
39. De Carvallo GS, Fourrey JL, Dodd RH, Da Silva AD (2009) Synthesis of a 4′,4′-spirothietane-2′,N3-cycloadenosine as a highly constrained analogue of 5′-deoxy-5′-methylthioadenosine (MTA). Tetrahedron Lett 50: 463-466.
40. Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11: 5-14.
41. Basu I, Cordovano G, Das I, Belbin TJ, Guha C, Schramm VL (2007) A transition state analogue of 5′-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers. J Biol Chem 282: 21477-21486.
42. Batova A, Cottam H, Yu J, Diccianni MB, Carrera CJ, Yu AL (2006) EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine. Blood 107: 898-903.